Drugs / MDX-1411
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00730652 | May 2009 → Dec 2012 | B-cell non-Hodgkin lymphoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00656734 | Apr 2008 → Jun 2010 | renal cell carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX 1411 | “MDX-1411 (fully human monoclonal antibody)” NCT00656734 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” NCT00656734 ↗ |
| Route | Intravenous | “administered as an i.v. infusion” NCT00656734 ↗ |
| Target | CD70 | “CD70 antigen cross-linking agent” CHEMBL2109492 ↗ |